Chiron Fluvirin Remediation Plan Design Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.
You may also be interested in...
FDA Announcement On Foreign Flu Vaccine Supply Expected By Dec. 3
The agency has completed inspections of foreign facilities and is considering whether the vaccines manufactured there are appropriate for use as investigational new drugs, HHS says.
FDA Announcement On Foreign Flu Vaccine Supply Expected By Dec. 3
The agency has completed inspections of foreign facilities and is considering whether the vaccines manufactured there are appropriate for use as investigational new drugs, HHS says.
Three Congressional Flu Hearings Planned For Next Week
The Senate Special Committee on Aging and the House Energy & Commerce and Government Reform Committees will hold hearings to discuss flu vaccine supply. FDA Acting Commissioner Lester Crawford and NIAID Director Anthony Fauci are expected to be among the witnesses.